Defibrotide Granted Orphan Drug Status in Australia

Published on : Sunday, November 17, 2013

GentiumGentium S.p.A. and Link Healthcare today announced that Defibrotide has been designated as an Orphan Drug for the Treatment of Hepatic Veno-Occlusive Disease (VOD).The sponsor of Defibrotide is Link Healthcare, Gentium’s exclusive distribution partner in Australia.

The main characteristics of the orphan drug policy in Australia are:
It is intended for drugs which aim to treat diseases with a prevalence of 2,000
patients/subjects or less in the Australian population (23 million).It allows for a waiver of application and evaluation and no annual registration fees.It provides five-year period of exclusivity (under consideration by the Australian jurisdiction).
Gentium will now work with Link to commence the Marketing Application process in


Source:-Gentium S.p.A.

Tags: ,

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

arrow2Follow TTW
facebook-logo  twitter-logo  LinkedIn_logo  stumbleupon-logo   rss_logo 
ttw_blogger_logo  ttw_blogger_logo  ttw_blogger_logo


  • 02 wtm_london17
  • 04 AIME 2018
  • 12 indywood 17
  • 16 TT Warsaw 2017
  • 18 TTF17
  • 19 Emitt 18
  • 19 IITM
  • 43 PATA


Get our toolbar!
Review on